Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2019

01-05-2019 | Sarcoma | Original Article

SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS

Authors: Ian Joseph Cohen, Helen Toledano, Jerry Stein, Yehuda Kollender, Eyal Fenig, Osnat Konen, Zvi Bar-Sever, Josephine Issakov, Meora Feinmesser, Smadar Avigad, Shifra Ash

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2019

Login to get access

Abstract

Purpose

We report the unexpected absence of early relapse (before 30 months) in 24 consecutive patients with isolated limb primary Ewing sarcoma treated with an intensified pilot protocol, SCMCIE94.

Methods

Clinical data for the study were collected retrospectively from the patient files. The protocol included 6 courses of chemotherapy, split radiation, and limb salvage surgery. This SCMCIE94 protocol had been used in almost all the patients described in an earlier report, in whom those with non-pelvic isolated tumors and low/absent CD56 expression in Ewing sarcoma tumor cells were all long-term survivors.

Results

The 5-year (10-year) event-free survival rate for the patients with isolated limb primary Ewing sarcoma was 78.95 ± 8.3% (68.6 ± 10.0%) and the overall survival rate was 90.7 ± 6.2% (71.1 ± 11.2%). There were no relapses before 30 months in any of these patients.

Conclusion

The intensified SCMCIE94 pilot protocol has been shown previously to cure patients with localized CD56-negative non-pelvic Ewing sarcoma. The present study shows that among all patients with localized extremity disease who were treated with this protocol, there were no cases of early relapse. Although our cohort was small, the difference in results from studies using other protocols is so striking, that it would seem reasonable to assume it is attributable to the changes made in the protocol itself rather than risk factors. Late relapses of isolated limb CD56-positive Ewing sarcoma suggest minimal residual disease warranting additional therapeutic approaches such as autologous stem cell rescue after Busulfan Melfelan.
Literature
1.
Jaffe N, Paed D, Traggis D, Salian S, Cassady JR (1976) Improved outlook for Ewing’s sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy. Cancer 38:1925–1930CrossRefPubMed
2.
Nesbit ME Jr, Gehan EA, Burgert EO Jr, Vietti TJ, Cangir A, Tefft M et al (1990) Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 8:1664–1674CrossRefPubMed
3.
Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ et al (2003) Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348:694–701CrossRefPubMed
4.
Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC et al (2015) Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 33:3036–3046CrossRef
5.
Ash S, Yaniv I, Toledano H, Stein J, Kollender Y, Fenig E et al (2018) Improved outcome in local Ewing Sarcoma with an intensified pilot treatment protocol SCMCIE94. J Ped Hematol Oncol 2018 (in press)
6.
Ash S, Luria D, Cohen IJ, Goshen Y, Toledano H, Issakov J al (2011) Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry. Clin Cancer Res 17:2900–2907CrossRefPubMed
7.
Dixon WJ (1993) BMDP statistical software. University of California Press, Los Angeles
8.
Rosen G, Caparros B, Hurvos AG et al (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of post operative chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 110:49;1221–1230
9.
Abdul-Karim FW, Buaer TW, Kilpatrick SC, Raymond KA, Siegal GP,. Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE et al (2012) Recommendations for the reporting of bone tumors. Hum Path (2004)35; 1173-1178.9. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 30:4148–4154CrossRef
10.
Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M et al (2009) Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol 27:2536–2541CrossRefPubMedPubMedCentral
11.
Ahmed SA, Randall RL, Dubois SG, Harmsen WS, Krailo M, Marcus KJ et al (2017) Identification of patients with localized ewing sarcoma at higher risk for local failure: a report from the childrens oncology group. Int J Radiat Oncol Biol Phys 99:1286–1294CrossRefPubMedPubMedCentral
12.
Rosen G, Caparros B, Nirenbirg A, Marcove RC, Huvos AG, Kosloff C, Lane J, Murphy ML (1981) Ewing sarcoma: ten year experience with adjuvant chemotherapy. Cancer 46:2204–2213CrossRef
13.
14.
Krasin MJ, Rodriguez-Galindo C, Billups CA, Davidoff AM, Neel MD, Merchant TE, Kun LE (2004) Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 60:830–838CrossRefPubMed
15.
Brown DC, Purushotham AD, Birnie GD, George WD (1995) Detection of intraoperative tumor cell dissemination in patients with breast cancer by use of reverse transcription and polymerase chain reaction. Surgery 1:96–101CrossRef
16.
Elomaa I, Blomqvist CP, Saeter G, Akerman M, Stenwig E, Wiebe T, Björk O, Alvegård TA (2000) Five-year results in Ewing’s sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. Eur J Cancer 36:875–880CrossRefPubMed
17.
Imran H, Enders E, Krailo M, Sim F, Okuno S, Hawkins D et al (2009) Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma. J Bone Jt Surg Am 91:604–612CrossRef
18.
Cohen IJ, Loven D, Shoenfeld T, Sandbank J, Kaplinsky C, Yaniv Y, Jaber L, Zaizov R (1991) Dactinomycin potentiation of radiation pneumonitis: a forgotten interaction. Ped Hematol Oncol 8:187–192CrossRef
19.
D’Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V et al (1981) The treatment of Wilms’ tumor: results of the Second National Wilms’ Tumor study. Cancer 47:2302–2311CrossRefPubMed
20.
Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R et al (1993) Carboplatin and vincristine for recurrent and newly diagnosed low grade glioma of childhood. J Clin Oncol 11:850–856CrossRefPubMed
21.
Lipshultz S, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR et al (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145–153CrossRefPubMed
22.
Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS et al (2007) Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol 25:493–500CrossRefPubMed
23.
Cvetković RS, Scott LJ (2006) Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 65:1005–1024CrossRef
24.
Reed DR, Hayashi M, Wagner L, Binitie O, Steppan DA, Brohl AS et al (2017) Treatment pathways of bone sarcoma in children, adolescents, and young adults. Cancer 123:2206–2218CrossRefPubMedPubMedCentral
25.
26.
Lipshultz SE, Giantris AL, Lipsitz SR, Dalton VK, Asselin BL, Barr RD,et al (2002) Doxorubicin administration by continuous infusion is not cardioprotective: the Dana Farber 91 – 01 acute lymphoblastic leukemia protocol. J Clin Oncol 20:1677–1682CrossRefPubMed
27.
Patel SR, Yadhan-Raj S, Papadopolous N, Plager C, Burgess A, Hayes C et al (1997) High dose ifosfamide in bone and soft tissue sarcomas: results of phase II and piolot studies-dose response and schedule dependence. J Clin Oncol 15:2378–2384CrossRefPubMed
28.
Morales-Arias J, Meyers PA, Bolontrade MF, Rodriguez N, Zhou Z, Reddy K et al (2007) Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration. Cancer 110:1568–1577CrossRefPubMed
29.
30.
Leavey PJ, Mascarenhas L, Marina N, Chen Z, Krailo M, Miser J et al, Children’s Oncology Group (2008) Prognostic factors for patients with Ewing Sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Children’s Oncology group. Blood Cancer 51:334–338CrossRef
31.
Barker LA, Pendergrass TW, Sanders JE, Hawkins DS (2005) Survival after recurrence of Ewing’s Sarcoma Family of tumors. J Clin Oncol 23:4354–4362CrossRefPubMed
32.
Whelan J, Le Delay MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N et al (2018) High-dose chemotherapy and blood autologous stem -cell rescue compared with standard chemotherapy in localized high-risk Ewing Sarcoma: results of euro-E.W.I.N.G99 and Ewing—2008. J Clin Oncol 36:31103119
33.
Marina NM, Pappo AS, Parham DM, Cain AM, Rao BN, Poquette CA et al (1999) Chemotherapy dose-intensification for pediatric patients with Ewing’s family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children’s Research Hospital. J Clin Oncol 17:180–190CrossRefPubMed
34.
Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P, Forni C, Manfrini M, Donati D, Picci P (2000) Prognostic factors in nonmetastatic Ewing’s sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 18:4–11CrossRefPubMed
35.
Kolb EA, Kushner BH, Gorlick R, Laverdiere C, Heley JH, LaQualglia MP et al (2003) Long-term event-free survival after intensive chemotherapy for Ewing’s family of tumors in children and young adults. J Clin Oncol 21:3423–3430CrossRefPubMed
36.
Swartz C, Constine LS, London WB, Sposto R, Friedman DL, Tebbi CK et al (2007) Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkins disease: a claim without evidence In reply. J Clin Oncol 25:4690–4691CrossRef
37.
Silber JH, Kaixer H (1988) Marginal analysis applied to the dose-response curve. Med Pediatr Oncol 16:344–348CrossRefPubMed
38.
Patel SR, Vadhan-Raj S, Papadopolous N, Plager MA, Burgess A, Hays S, Benjamin RS (1997) High dose Ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies—dose-response and schedule dependence. J Clin Oncol 15:2378–2384CrossRefPubMed
Metadata
Title
SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS
Authors
Ian Joseph Cohen
Helen Toledano
Jerry Stein
Yehuda Kollender
Eyal Fenig
Osnat Konen
Zvi Bar-Sever
Josephine Issakov
Meora Feinmesser
Smadar Avigad
Shifra Ash
Publication date
01-05-2019
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-019-03789-3

Other articles of this Issue 5/2019

Cancer Chemotherapy and Pharmacology 5/2019 Go to the issue

Original Article

Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma: a real-life report

Letter to the Editor

The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma

Short Communication

Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38

Original Article

The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men

Original Article

Regorafenib regressed a doxorubicin-resistant Ewing’s sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model

Original Article

Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits